Neuroimmunology Program - IDIBAPS

Raman Spectroscopy and Tecfidera®

Which are the aims?

It is an observational study in patients with multiple sclerosis who start treatment with Tecfidera®. Raman Spectroscopy informs about concentration of metabolites in the retina. We are going to evaluate concentrations of inflammatory, oxidative stress and excitotoxicity molecules before and after starting treatment with Tecfidera®. These changes will be valuable in order to understand the potential of this technology to predict the patient´s response to the therapy.

Which are the results so far?

We have almost finished the recruitment of this project. So, we expect to be able to communicate the results by third quarter of 2017

What are we looking for and how could you help us?

If you are a patient, we would like to encourage you to participate in this study that will not interfere with standard healthcare in your hospital. We will provide you with all the results so they will be available for your treating physician´s evaluation at your reference hospital.